Quadruple negative breast cancer.

Quadruple negative breast cancer. Breast Cancer. 2020 Jan 14;: Authors: Huang M, Wu J, Ling R, Li N Abstract Quadruple negative breast cancer (QNBC), lacking the expression of ER (estrogen receptor), PR (progesterone receptor), HER2 (human epidermal growth factor receptor-2) and AR (androgen receptor), was regarded as one breast cancer subtype with the worst prognosis. Recently, the molecular features of QNBC are not well understood. Different from AR-positive triple-negative breast cancer, QNBC is insensitive to conventional chemotherapeutic agents and has no efficient treatment targets. However, QNBC has been shown to express unique proteins that may be amenable to use in the development of targeted therapies. Here we reviewed the features of QNBC and proteins that may serve as effective targets for QNBC treatment, such as ACSL4, SKP2, immune checkpoint inhibitors, EGFR, MicroRNA signatures and Engrailed 1. PMID: 31939077 [PubMed - as supplied by publisher]
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research

Related Links:

ConclusionPharmacokinetic quantitative parameters with histogram and texture features obtained from DCE-MRI are associated with the molecular subtypes of breast cancer, and may serve as potential imaging biomarkers to differentiate between the luminal A and luminal B molecular subtypes.
Source: Academic Radiology - Category: Radiology Source Type: research
ConclusionesLa colocación de semillas de 125I es una técnica factible para la localización intraoperatoria del ganglio positivo biopsiado en combinación con la BGC. El resultado anatomopatológico del GM permite determinar el estatus axilar posneoadyuvancia.AbstractObjectiveTo present our initial experience in the combined procedure of intraoperative detection of axillary positive node marked with 125I seed (ML) and sentinel node biopsy (SLN) after neoadjuvant chemotherapy (NACT), in breast cancer patients.Material and methodsProspective study, January 2017 – March 2019, 16 breast ca...
Source: Revista Espanola de Medicina Nuclear e Imagen Molecular - Category: Nuclear Medicine Source Type: research
The FDA granted a priority review to a new drug application submitted by Seattle Genetics, Inc. for tucatinib to treat patients with HER2-positive breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Our study shows that receiving lapatinib with food can increase its plasma concentration with no significantly increased drug-related toxicity. We suggest that a larger-sample-size clinical trial is needed to fully understand the effect of administration of lapatinib with food. PMID: 32058619 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
ConclusionAdministration of adjuvant eribulin after neoadjuvant chemotherapy was feasible and well tolerated. The 24-month DFS rate did not reach the study target levels in any of the cohorts and was similar to DFS previously described in these cohorts following neoadjuvant chemotherapy alone.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Condition:   Breast Cancer Intervention:   Drug: 99mTc-HPArk2 Sponsor:   Peking Union Medical College Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this study we analyzed these tumor markers in order to identify breast cancer cutaneous metastatic profiles. A cohort of 26 primary tumors from breast cancer patients with cutaneous metastases were included; also, cutaneous and lymphatic node metastatic samples and primary tumors from breast cancer patients without metastases were analysed. Immunohistochemical (IHC) studies demonstrated that both underglycosylated MUC1 (uMUC1) and sialyl Lewis x (sLex) to be positively associated with cutaneous metastatic primary tumors (p 200 kDa was also the site for binding of anti-sLex MAb; in coincidence, a high corre...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Our study demonstrated that biological subtype based on the classification standard from the St Gallen International Breast Cancer Conference (2013) Expert Panel serves as a reliable prognostic predictor for Chinese breast cancer patients receiving PMRT. Treatment with trastuzumab and endocrine therapy dramatically decreased the risk of LRR in HER2 ‐positive and hormonal receptor‐positive patients. AbstractAimTo investigate the impact of biological subtypes in locoregional recurrence in Chinese breast cancer patients receiving postmastectomy radiotherapy (PMRT).Methods and MaterialsAbout 583 patients who received postm...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
This article presents a critical appraisal of two treatments commonly used in the treatment of metastatic HER2-positive breast cancer: the oral chemotherapy drug, capecitabine, and the monoclonal antibody, trastuzumab. What follows is a critical discussion of the pharmacotherapeutics of capecitabine and trastuzumab, which considers their use both as single agents and as a combination regimen in the treatment of metastatic breast cancer. The implications of side effects of these drugs are discussed, both individually and in combination, as are the challenges these bring to the prescriber. The article evaluates the use of th...
Source: British Journal of Nursing - Category: Nursing Authors: Tags: Br J Nurs Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2